{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:03:54Z","timestamp":1784610234842,"version":"3.55.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is highly aggressive with poor prognosis and limited treatment options. Immune checkpoint inhibitors (ICIs) combined with chemotherapy have emerged as a promising strategy for advanced TNBC. This umbrella meta-analysis was conducted to comprehensively evaluate the efficacy and safety of this combination regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Web of Science, and Embase for relevant articles up to August 2025. The methodological quality and evidence certainty of the included studies were assessed using AMSTAR\u22122, GRADE, and a prespecified classification scheme. Publication bias was examined through funnel plots and Egger\u2019s tests, and sensitivity analyses were performed to test result robustness. The appropriate effect model was selected based on heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11 meta analyses comprising 39,147 patients were included. ICIs combined with chemotherapy significantly improved overall survival (OS, HR\u00a0=\u00a00.89) and progression-free survival (PFS, HR\u00a0=\u00a00.81) compared with chemotherapy alone. The objective response rate showed no statistically significant improvement in either programmed cell death ligand-1 (PD-L1)-negative (RR\u00a0=\u00a01.01) or PD-L1-positive (RR\u00a0=\u00a01.17) populations. Regarding safety, combination therapy was associated with increased risks of all-grade and grade \u22653 adverse events(AEs), as well as a higher incidence of immune-related adverse events(irAEs). Findings concerning hepatitis require cautious interpretation due to the limited number of studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICIs combined with chemotherapy confers survival benefits in advanced TNBC, though at the cost of increased immune-related toxicity. Given current evidence limitations, future research with more detailed stratification is needed to guide individualized treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251168274.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1900242","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:20:42Z","timestamp":1784607642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Wendi","family":"Cao","sequence":"first","affiliation":[{"name":"Clinical Medicine College, Graduate School of Qinghai University","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxi","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qinghai Red Cross Hospital","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingheng","family":"Song","sequence":"additional","affiliation":[{"name":"Clinical Medicine College, Graduate School of Qinghai University","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology Surgery, Affiliated Hospital of Qinghai University","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qinghai Red Cross Hospital","place":["Xining, Qinghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30215-1","article-title":"Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study","volume":"8","author":"Heer","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design","volume":"9","author":"Kassam","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21775","article-title":"Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro","volume":"119","author":"Blank","year":"2006","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: key trials and an emerging role in breast cancer","volume":"79","author":"Gaynor","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-19-3020","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e13140","article-title":"Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in triple-negative breast cancer: a focus on survival, metastasis, and recurrence","volume":"43","author":"Trujillo Asturias","year":"2025","journal-title":"Breast Cancer-Metastatic"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1060308","article-title":"PD-L1 expression as biomarker of efficacy of PD-1\/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: a systematic review and meta-analysis","volume":"14","author":"Khan","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/ol.2024.14803","article-title":"PD-1\/PD-L1 inhibitor-based immunotherapy in locally advanced or metastatic triple-negative breast cancer: a meta-analysis","volume":"29","author":"Chen","year":"2025","journal-title":"Oncol Lett"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1186\/s12885-024-13105-9","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1309677","article-title":"Addition of PD-1\/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis","volume":"14","author":"Yang","year":"2024","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.795650","article-title":"Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer: a systematic review and meta-analysis","volume":"11","author":"Ji","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03396-6","article-title":"Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis","volume":"26","author":"Wang","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2025.103783","article-title":"Efficacy and safety of immunochemotherapy in advanced triple-negative breast cancer: a meta-analysis of randomised clinical trials","volume":"40","author":"Shen","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1186\/s12885-022-10225-y","article-title":"Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"22","author":"Sharmni Vishnu","year":"2022","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/11795549241308072","article-title":"Efficacy and safety of paclitaxel-based PD-1\/PD-L1 immunotherapies for triple-negative breast cancer: a systematic review and network meta-analysis","volume":"18","author":"Dai","year":"2024","journal-title":"Clin Med Insights Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.11.007","article-title":"Systematic review finds overlapping reviews were not mentioned in every other overview","volume":"67","author":"Pieper","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"CMAJ"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased","volume":"316","author":"Irwig","year":"1998","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jopan.2025.01.001","article-title":"The effects of early oral intake in the postanesthesia care unit on nausea and vomiting: a meta-analysis of randomized controlled trials","volume":"40","author":"Kang","year":"2025","journal-title":"J Perianesth Nurs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3428","article-title":"The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis","volume":"27","author":"Biggerstaff","year":"2008","journal-title":"Stat Med"},{"key":"B45","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"B48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000059","article-title":"Biochemical signaling of PD-1 on T cells and its functional implications","volume":"20","author":"Boussiotis","year":"2014","journal-title":"Cancer J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S499373","article-title":"Unveiling the landscape of PD-L1 expression and tumor-infiltrating lymphocyte subtypes in advanced triple-negative breast cancer in Brazil","volume":"17","author":"Dos Santos","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155556","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes: Correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping","volume":"262","author":"Li","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04039-z","article-title":"The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a review","volume":"486","author":"Andour","year":"2025","journal-title":"Virchows Arch"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07561-x","article-title":"Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort","volume":"210","author":"Sigurjonsdottir","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104808","article-title":"T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors","volume":"213","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1774615","article-title":"Role of innate immunity in the development of cancer immunotherapy immune-mediated adverse events","volume":"17","author":"Sierra-Salazar","year":"2026","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2025.101265","article-title":"Efficacy and safety of immunotherapy combined with chemotherapy in both neoadjuvant and adjuvant settings among triple-negative breast cancer: A meta-analysis of randomized clinical trials","volume":"61","author":"Han","year":"2026","journal-title":"Curr Probl Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1584675","article-title":"Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms","volume":"16","author":"Mao","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1900242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:20:43Z","timestamp":1784607643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1900242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":63,"alternative-id":["10.3389\/fonc.2026.1900242"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1900242","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1900242"}}